Pioneering Immune-Modulating Therapies
Airway Therapeutics is a clinical-stage biopharmaceutical company advancing a new class of biologic therapies to drive a step change in the prevention and treatment of respiratory, inflammatory, and infectious diseases.
Our lead therapeutic candidate, zelpultide alfa, is an immune-modulating protein designed to reduce harmful inflammation and protect against infection in diseases driven by immune dysregulation, delivering first-in-class solutions for vulnerable patients.
Currently in Phase 2b/3 development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm neonates, zelpultide alfa is being advanced with plans to expand into additional respiratory, inflammatory, and infectious indications across all age groups.
